Literature DB >> 20706865

CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres.

Margaret Durko1, Carol Allen, Josephine Nalbantoglu, George Karpati.   

Abstract

Duchenne muscular dystrophy is a genetic muscle disease characterized by the absence of sub-sarcolemmal dystrophin that results in muscle fibre necrosis, progressive muscle wasting and is fatal. Numerous experimental studies with dystrophin-deficient mdx mice, an animal model for the disease, have demonstrated that extrasynaptic upregulation of utrophin, an analogue of dystrophin, can prevent muscle fibre deterioration and reduce or negate the dystrophic phenotype. A different approach for ectopic expression of utrophin relies on augmentation of CT-GalNAc transferase in muscle fibre. We investigated whether CT-GalNAc transferase overexpression in adult mice influence appearance of utrophin in the extrasynaptic sarcolemma. After electrotransfer of plasmid DNA carrying an expression cassette of CT-GalNAc transferase into tibialis anterior muscle of wild type and dystrophic mice, muscle sections were examined by immunofluorescence. CT-GalNAc transgene expression augmented sarcolemmal carbohydrate glycosylation and was accompanied by extrasynaptic utrophin. A 6-week time course study showed that the highest efficiency of utrophin overexpression in a plasmid harboured muscle fibres was 32.2% in CD-1 and 52% in mdx mice, 2 and 4 weeks after CT-GalNAc gene transfer, respectively. The study provides evidence that postnatal CT-GalNAc transferase overexpression stimulates utrophin upregulation that is inherently beneficial for muscle structure and strength restoration. Thus CT-GalNAc may provide an important therapeutic molecule for treatment of dystrophin deficiency in Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706865     DOI: 10.1007/s10974-010-9222-9

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  48 in total

1.  Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase -- increased expression with reduced muscle damage.

Authors:  J M McMahon; E Signori; K E Wells; V M Fazio; D J Wells
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

2.  Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.

Authors:  J A Rafael; J M Tinsley; A C Potter; A E Deconinck; K E Davies
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

Review 3.  Function and genetics of dystrophin and dystrophin-related proteins in muscle.

Authors:  Derek J Blake; Andrew Weir; Sarah E Newey; Kay E Davies
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

4.  Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.

Authors:  R Fisher; J M Tinsley; S R Phelps; S E Squire; E R Townsend; J E Martin; K E Davies
Journal:  Neuromuscul Disord       Date:  2001-11       Impact factor: 4.296

5.  Discordant expression of utrophin and its transcript in human and mouse skeletal muscles.

Authors:  A O Gramolini; G Karpati; B J Jasmin
Journal:  J Neuropathol Exp Neurol       Date:  1999-03       Impact factor: 3.685

6.  Distinct structures and functions of related pre- and postsynaptic carbohydrates at the mammalian neuromuscular junction.

Authors:  P T Martin; L J Scott; B E Porter; J R Sanes
Journal:  Mol Cell Neurosci       Date:  1999-02       Impact factor: 4.314

7.  Postnatal changes in sarcolemmal organization in the mdx mouse.

Authors:  Patrick Reed; Robert J Bloch
Journal:  Neuromuscul Disord       Date:  2005-08       Impact factor: 4.296

8.  Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice.

Authors:  Holly H Nguyen; Vianney Jayasinha; Bing Xia; Kwame Hoyte; Paul T Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

9.  Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy.

Authors:  Jeong Yun Shim; Tai Seung Kim
Journal:  Yonsei Med J       Date:  2003-02       Impact factor: 2.759

10.  Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA.

Authors:  K W Liang; M Nishikawa; F Liu; B Sun; Q Ye; L Huang
Journal:  Gene Ther       Date:  2004-06       Impact factor: 5.250

View more
  6 in total

Review 1.  The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy.

Authors:  Jamie L Marshall; Yukwah Kwok; Brian J McMorran; Linda G Baum; Rachelle H Crosbie-Watson
Journal:  FEBS J       Date:  2013-05-13       Impact factor: 5.542

2.  Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration.

Authors:  Jamie L Marshall; Johan Holmberg; Eric Chou; Amber C Ocampo; Jennifer Oh; Joy Lee; Angela K Peter; Paul T Martin; Rachelle H Crosbie-Watson
Journal:  J Cell Biol       Date:  2012-06-25       Impact factor: 10.539

3.  Sarcospan increases laminin-binding capacity of α-dystroglycan to ameliorate DMD independent of Galgt2.

Authors:  Hafsa Mamsa; Rachelle L Stark; Kara M Shin; Aaron M Beedle; Rachelle H Crosbie
Journal:  Hum Mol Genet       Date:  2022-03-03       Impact factor: 5.121

4.  Sarcospan: a small protein with large potential for Duchenne muscular dystrophy.

Authors:  Jamie L Marshall; Rachelle H Crosbie-Watson
Journal:  Skelet Muscle       Date:  2013-01-03       Impact factor: 4.912

5.  Mitochondrial glycerol 3-phosphate dehydrogenase promotes skeletal muscle regeneration.

Authors:  Xiufei Liu; Hua Qu; Yi Zheng; Qian Liao; Linlin Zhang; Xiaoyu Liao; Xin Xiong; Yuren Wang; Rui Zhang; Hui Wang; Qiang Tong; Zhenqi Liu; Hui Dong; Gangyi Yang; Zhiming Zhu; Jing Xu; Hongting Zheng
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

6.  Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.

Authors:  Patricia Soblechero-Martín; Andrea López-Martínez; Laura de la Puente-Ovejero; Ainara Vallejo-Illarramendi; Virginia Arechavala-Gomeza
Journal:  Neuropathol Appl Neurobiol       Date:  2021-06-04       Impact factor: 8.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.